|
Composition
|
Name
|
Composition
|
Institution
|
|
Eduardo López Granados
|
Coordinador de Inmunología
|
Hospital Universitario La Paz
|
|
María Bravo García-Morato
|
Facultativo Especialista de Área en Inmunología
|
Hospital Universitario La Paz
|
|
Carmen Cámara Hijón
|
Facultativo Especialista de Área en Inmunología
|
Hospital Universitario La Paz
|
|
Álvaro Clemente Bernal
|
Técnico de Grado Superior
|
FIBHULP
|
|
Ricardo Cuesta Martín de la Cámara
|
Biólogo Interno Residente en la especialidad de Inmunología
|
Hospital Universitario La Paz
|
|
Andrea González Torbay
|
Médico Interno Residente en Inmunología
|
Hospital Universitario La Paz
|
|
Carla Cecilia Gianellli
|
Facultativo Especialista de Área en Inmunología
|
Hospital Universitario La Paz
|
|
Diego Plaza López de Sabando
|
Facultativo Especialista de Área en Hemato-Oncología Pediátrica
|
Hospital Universitario La Paz
|
|
Keren Reche Yebra
|
Técnico de Laboratorio
|
FIBHULP
|
|
Ángel Julián Robles Marhuenda
|
Facultativo Especialista de Área en Medicina Interna
|
Hospital Universitario La Paz
|
|
Rebeca Rodríguez Pena
|
Facultativo Especialista de Área en Inmunología
|
Hospital Universitario La Paz
|
|
María Carmen Salcedo Moreno
|
Técnico de Laboratorio
|
Hospital Universitario La Paz
|
|
Elena Sánchez Zapardiel
|
Facultativo Especialista de Área en Inmunología
|
Hospital Universitario La Paz
|
|
Ana Sastre Urguelles
|
Facultativo Especialista de Área en Hemato-Oncología Pediátrica
|
Hospital Universitario La Paz
|
|
Juan Manuel Torres Canizales
|
Médico Inmunólogo
|
Hospital Universitario La Paz
|
Strategic Objective
Our group attempts to unravel the molecular bases of primary immunodeficiencies (PIDs), a large group of rare conditions (more that 350 types described so far) that virtually affect any cell type of the immune system and increase the risk of infections, autoimmunity and cancer in patients. We take a multidisciplinary clinical, anatomic, genetic, epigenetic and functional approach. By correlating clinical and experimental data, we aim to achieve a better understanding of these rare diseases and lay the grounds for, repurposed or new, more effective treatments.
Taking advantage of the knowledge and resources developed to dissect the immune system in PIDs, we are developing new schemes for immune monitoring of transplanted patients, to better estimate immunosupresion and tolerance, and early detection of severe complications as infections and rejection. Finally, we explore novel approaches for monitoring, and fine tuning of immunotherapies
Research Lines
• To define the anatomical, cellular, molecular and (epi)genetic bases of immunological dysfunction in patients diagnosed with primary immunodeficiency in our clinic.
• The maturation and functional specialization of human B lymphocytes, and its pathophysiology in primary and secondary antibody immunodeficiencies.
• The analysis of the immunological reconstitution after haemopoietic stem cell transplantation, and the discovery and clinical validation of immunological biomarkers for immunosuppression and tolerance in solid organ transplantation.
• The development and clinical implementation of patient-tailored monitoring schemes of immunotherapies in wide clinical use.
|